Successful management of central nervous system manifestations of chronic graft-vs-host disease: a case report

References

• Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2015;21(2):266–274.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215–233.
   PubMed Web of Science ®Google Scholar
• Ruggiu M, Cuccuini W, Mokhtari K, et al. Case report: central nervous system involvement of human graft versus host disease: report of 7 cases and a review of literature. Medicine (Baltimore). 2017;96(42):e8303.
   PubMed Web of Science ®Google Scholar
• Cuvelier GDE, Schoettler M, Buxbaum NP, et al. Toward a better understanding of the atypical features of chronic graft-versus-host disease: a report from the 2020 national institutes of health consensus project task force. Transplant Cell Ther. 2022;28(8):426–445.
   PubMedGoogle Scholar
• Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017;23(2):211–234.
   PubMed Web of Science ®Google Scholar
• Adams RC, Carter-Cusack D, Shaikh SN, et al. Donor bone marrow-derived macrophage MHC II drives neuroinflammation and altered behavior during chronic GVHD in mice. Blood. 2022;139(9):1389–1408.
   PubMed Web of Science ®Google Scholar
• Mohrmann RL, Mah V, Vinters HV. Neuropathologic findings after bone marrow transplantation: an autopsy study. Hum Pathol. 1990;21(6):630–639.
   PubMed Web of Science ®Google Scholar
• Grauer O, Wolff D, Bertz H, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the consensus conference on clinical practice in chronic graft-versus-host disease. Brain. 2010;133(10):2852–2865.
   PubMedGoogle Scholar
• Johnson-Johnson. Imbruvica (ibrutinib). U.S. Food and Drug Administration. Revised April 2020. [Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/205552s030,210563s006lbl.pdf.
   Google Scholar
• Administration UFaD. FDA approves treatment for chronic graft versus host disease. August 2, 2017. Available from https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm569710.htm.
   Google Scholar
• Padovan CS, Bise K, Hahn J, et al. Angiitis of the central nervous system after allogeneic bone marrow transplantation? Stroke. 1999;30(8):1651–1656.
   PubMed Web of Science ®Google Scholar
• Ma M, Barnes G, Pulliam J, et al. CNS angiitis in graft vs host disease. Neurology. 2002;59(12):1994–1997.
   PubMed Web of Science ®Google Scholar
• Campbell JN, Morris PP. Cerebral vasculitis in graft-versus-host disease: a case report. AJNR Am J Neuroradiol. 2005;26(3):654–656.
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Kamio Y, Kato N, et al. Extracranial-intracranial bypass for cerebral vasculitis after graft-versus-host disease: case report and review of the literature. World Neurosurg. 2019;123:193–196.
   PubMed Web of Science ®Google Scholar
• Sostak P, Padovan CS, Eigenbrod S, et al. Cerebral angiitis in four patients with chronic GVHD. Bone Marrow Transplant. 2010;45(7):1181–1188.
   PubMed Web of Science ®Google Scholar
• Thom V, Arumugam TV, Magnus T, et al. Therapeutic potential of intravenous immunoglobulin in acute brain injury. Front Immunol. 2017;8:875.
   PubMed Web of Science ®Google Scholar
• Li Y, Gao F, Sun W, et al. Cerebral large artery occlusion in chronic graft-versus-host disease: a case report. Medicine. 2021;100(51):e28263.
   PubMed Web of Science ®Google Scholar
• Soussain C, Choquet S, Blonski M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II ‘proof-of-concept’ iLOC study by the lymphoma study association (LYSA) and the french oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121–130.
   PubMed Web of Science ®Google Scholar
• Im A, Hakim FT, Pavletic SZ. Novel targets in the treatment of chronic graft-versus-host disease. Leukemia. 2017;31(3):543–554.
   PubMed Web of Science ®Google Scholar
• Chin KK, Kim HT, Inyang EA, et al. Ibrutinib in steroid-refractory chronic graft-versus-host disease, a single-center experience. Transplant Cell Ther. 2021;27(12):990.e1–e7.
   PubMedGoogle Scholar
• Waller EK, Miklos D, Cutler C, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study. Biol Blood Marrow Transplant. 2019;25(10):2002–2007.
   PubMed Web of Science ®Google Scholar
• Subramonian A, Farrah K. CADTH rapid response reports. Brivaracetam versus levetiracetam for epilepsy: a review of comparative clinical safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.; 2020.
   Google Scholar